Spruce biosciences to participate in the h.c. wainwright 25th annual global investment conference

South san francisco, calif.--(business wire)---- $sprb--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that javier szwarcberg, m.d., m.p.h., chief executive officer, will present at the h.c. wainwright 25th annual global investment conference on september 12, 2023, at 3:30 p.m. et. interested parties can access the live webcast here.
SPRB Ratings Summary
SPRB Quant Ranking